For Patients & Caregivers
Bottom Line: Emblica officinalis has antioxidant effects. It has not been shown to treat cancer in humans.
E. officinalis is commonly used in Ayurveda, the traditional medicinal system of India, for various ailments including diarrhea, jaundice, headaches, inflammation, and as a tonic. It is also one of the constituents of a popular Ayurvedic formulation, Triphala. All parts of the tree including the dried and fresh fruits, seeds, leaves, root bark, and flowers are used.
Laboratory studies and studies done in animals suggest that E. officinalis has antioxidant, antibacterial, liver protective, cardioprotective, antiulcer, antitumor, antidiabetic properties. Small studies in humans show that it has antioxidant and lipid-lowering effects.
A small study showed that E. officinalis reduces HDL cholesterol and improves LDL levels in diabetic individuals.
Studies in mice that indicate that E. officinalis may inhibit tumor growth. However, human studies are needed in order to confirm this effect.
- Cardioprotective Effects
Lab studies suggest protective effects against doxorubicin toxicity.
There is no scientific evidence to support this use.
Used in traditional medicine for jaundice. Clinical data are lacking.
Animal studies suggest E. officinalis can reduce fever and pain.
E. officinalis was shown to reduce inflammation in lab studies. Human data are lacking.
- Chronic ulcers
Traditional use and results from lab studies support this use.
Data from lab studies and small human studies indicate hyperlipidemic effects.
This study was done to determine whether an E. officinalis extract supplement can reduce oxidative stress. Seventeen uremic (accumulation of constituents in the blood that are normally eliminated in the urine) patients were enrolled and received E. officinalis supplements for 4 months. Researchers found that the supplements reduced a plasma oxidative marker and increased plasma total antioxidant status. They concluded that E. officinalis supplementation may decrease oxidative stress in uremic patients.
For Healthcare Professionals
Emblica officinalis is a deciduous tree prevalent in some parts of Asia. All parts of the tree, especially the fruit, are commonly used in traditional medicine for various ailments including diarrhea, jaundice, headaches, inflammation, and as a tonic (1). It is also one of the constituents of a popular Ayurvedic formulation, Triphala.
The activity of E. officinalis is often attributed to its antioxidant constituents, such as ascorbic acid, polyphenols, flavonoids, and tannins (2)(3). In vitro and in vivo studies indicate antioxidant (1)(4)(5), antibacterial (6), hepatoprotective (7) , cardioprotective (3) radioprotective (8), antiulcerogenic (9), antitumor (10), analgesic (11), antidiabetic (12), and antihyperlipidemic (13) properties.
Clinical data are limited to a few studies that show benefit in patients with uremia (accumulation of constituents in the blood that are normally eliminated in the urine) by reducing oxidative stress(5); improving HDL and lower LDL-cholesterol levels in diabetic patients (16); and lowering lipid levels and blood pressure in patients with hyperlipidemia (17).
Because E. officinalis exhibits strong antioxidant effects, it may interfere with chemotherapy and radiation therapy.
The antioxidant activity of E. officinalis is attributed to the high content of ascorbic acid (4) but it was discovered that such effects may be due to the tannins, Emblicanin A and Emblicanin B (1). The antidiabetic property of E. officinalis is thought to be due to its ability to reduce release of inflammatory cytokines that cause insulin resistance (12). E. officinalis may also play a role in preventing age-related hyperlipidemia by reducing nitric oxide synthase and cyclooxygenase-2 (COX-2) protein levels via inhibiting NF-kappa B activation (13). In another study, E. officinalis extracts were shown to induce apoptosis in mature osteoclasts, an effect that may limit bone resorption in pathologies associated with bone loss (15).
A hydroalcoholic extract of E. officinalis demonstrated anti-inflammatory effects by increasing glutathione, superoxide dismutase, and catalase activities, and subsequently decreasing lipid peroxidation (19).
Several studies have investigated the antitumor properties of E. officinalis. Pyrogallol, a component of E. officinalis extract, was found to cause cell cycle arrest in the G2/M phase, inhibit proliferation, and induce apoptosis in human lung adenocarcinoma (H441) and squamous cell cancer (H520) cell lines (2). Intraperitoneal pyrogallol injections also suppressed subcutaneous tumor growth in mice (2). An aqueous extract decreased tumor volume through inhibiting the cell cycle regulating enzyme CDC25 (10).
Progallin extracted from E. officinalis leaves also caused cell cycle arrest in the G1/M and G2/M phase, inhibited proliferation, and induce apoptosis in human hepatocellular carcinoma cells (BEL-7404) (14).
In other studies, E. officinalis extracts were shown to inhibit cell growth both in vitro and in vivo possibly via inhibition of angiogenesis and activation of autophagy in ovarian cancer cells (20); and demonstrated cardioprotective effects against doxorubicin toxicity in vitro (3), attributed to the antioxidants.
Chen TS, et al. Supplementation of Emblica officinalis (Amla) extract reduces oxidative stress in uremic patients. Am J Chin Med. 2009;37(1):19-25.
This study was conducted to determine whether an E. officinalis extract can reduce oxidative stress. Seventeen uremic patients were enrolled and received E. officinalis supplementation for 4 months. Study results indicated that compared to baseline, the supplements reduced the plasma oxidative marker, 8-isoprostaglandin (1415 + 1234 pg/ml vs 750 + 496 pg/ml, p<0.05) and increased plasma total antioxidant status (2.32 + 0.14 mM vs 2.55 + 0.24 mM, p<0.05) in uremic patients. No significant differences in liver (GOP or GPT) or renal function (creatinine, blood urea nitrogen, and uric acid), diabetic (glucose and adiponectin) or atherogenic (LDL/HDL ratio, total cholesterol and homosysteine) indices were observed.
The investigators concluded that E. officinalis supplementation may play a role in decreasing oxidative stress in uremic patients.